Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Clinical Oncology

• Publication date

  2008-10-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2008.16.3832PMID 18725648
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

  2008cited by this paper
• Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

  2007cited by this paper
• Recent perspectives of endocrine therapy for breast cancer

  2007cited by this paper
• Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.

  2007cited by this paper
• Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

  2007cited by this paper
• Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

  2007cited by this paper
• Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.

  2007cited by this paper
• Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.

  2007cited by this paper
• Denosumab in postmenopausal women with low bone mineral density.

  2006cited by this paper
• Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

  2006cited by this paper
• The ne w e ngl and j our na l of medicine

  2006cited by this paper
• Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial.

  2006influential reference
• Role of osteoblasts in hormonal control of bone resorption—A hypothesis

  2006cited by this paper
• A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

  2006cited by this paper
• Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.

  2005cited by this paper
• Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.

  2005cited by this paper
• Long-term effects of aromatase inhibitors on bone.

  2005cited by this paper
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

  2005cited by this paper
• A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

  2004cited by this paper
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  2004cited by this paper
• American society of clinical oncology 2003 update on the role of biophosphonates and bone health issues in women with breast cancer

  2004cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

  2003cited by this paper
• American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.

  2003cited by this paper
• American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

  2003cited by this paper
• A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

  2003cited by this paper
• American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

  2002cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  2002cited by this paper
• Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

  2001cited by this paper
• The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts

  1999cited by this paper
• Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

  1998cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998cited by this paper
• Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

  1998cited by this paper
• osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

  1998cited by this paper
• Prevention of bone loss with alendronate in postmenopausal women under 60 years of age.

  1998cited by this paper
• Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

  1998cited by this paper
• A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

  1989cited by this paper
• Printed in Great Britain

  1970cited by this paper

• Effectiveness and safety of bone protective interventions to mitigate bone loss and skeletal fractures experienced by patients with non-metastatic breast cancer: a systematic review and meta-analysis.

  2026cites this paper
• Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer.

  2026cites this paper
• Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?

  2026influential citation
• Bone health in patients with cancer: a SEOM-SEIOMM consensus review of risk factors, assessment strategies, and management approaches.

  2026cites this paper
• Comparative effectiveness of bone-protective interventions for aromatase inhibitors-induced bone loss in postmenopausal women with early breast cancer: a network meta-analysis

  2026cites this paper
• Identification and Management of Late toxicities after Radiotherapy for Vulvar Cancer.

  2025cites this paper
• Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab

  2025cites this paper
• Cardiovascular adverse events associated with denosumab versus zoledronic acid in patients with breast cancer: a propensity score overlap weighted analysis

  2025cites this paper
• Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures

  2025cites this paper
• Management of Adverse Effects of Endocrine Therapy in Early-Stage Breast Cancer: Pharmacological and Nonpharmacological Approaches.

  2025cites this paper
• Bone Effects of Anti-Cancer Treatments in 2024

  2025cites this paper
• Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)

  2025cites this paper
• Health Outcomes in Fragility Fractures in the Spanish Registry of Osteoporotic Fractures According to the FLS Care Model.

  2025cites this paper
• Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti‐Oestrogen Therapy for Breast Cancer

  2025cites this paper
• Bone turnover markers as predictors of hypocalcemia in patients with bone metastases receiving denosumab

  2025cites this paper
• Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial

  2025cites this paper
• Navigating skeletal wellness after breast cancer.

  2025cites this paper
• Approach to Bone Health in the Patient with Breast Cancer.

  2024cites this paper
• Exploring Denosumab in the Treatment of Giant Cell Tumors: Clinical Evidence and Controversies

  2024cites this paper
• From Evidence to Practice: Denosumab in Osteoporosis and Joint Health

  2024cites this paper
• Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT

  2024cites this paper
• Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis.

  2024cites this paper
• Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial

  2024cites this paper
• Cancer treatment-induced bone loss

  2024cites this paper
• Effect of bisphosphonate and denosumab treatment on TBS in Japanese breast cancer patients with AIBL

  2024cites this paper
• Extra-osseous Roles of the RANK-RANKL-OPG Axis with a Focus on Skeletal Muscle

  2024cites this paper
• The use of denosumab in osteoporosis – an update on efficacy and drug safety

  2024cites this paper
• Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital

  2024cites this paper
• The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy

  2023cites this paper
• Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting

  2023cites this paper
• Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer

  2023cites this paper
• Efficacy and safety of COVID-19 vaccines for patients with spinal tumors receiving denosumab treatment: An initial real−clinical experience study

  2023cites this paper
• What Is Known about Breast Cancer in Young Women?

  2023cites this paper
• Bone health in breast cancer.

  2023cites this paper
• The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis

  2023influential citation
• Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials

  2023cites this paper
• Antiresorptive Medications Prior to Stereotactic Body Radiotherapy for Spinal Metastasis are Associated with Reduced Incidence of Vertebral Body Compression Fracture

  2023cites this paper
• Bone modifying agents in postmenopausal breast cancer patients treated with aromatase inhibitors: beyond bone protection?

  2023influential citation
• Impact of Physical Rehabilitation on Bone Biomarkers in Non-Metastatic Breast Cancer Women: A Systematic Review and Meta-Analysis

  2023cites this paper
• Review of bone health in women with estrogen receptor–positive breast cancer receiving endocrine therapy

  2023cites this paper
• Biologic Antiresorptive: Denosumab

  2023cites this paper
• Advances in the care of breast cancer survivors

  2023cites this paper
• Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.

  2022cites this paper
• Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer

  2022influential citation
• Research progress of bone-targeted drug delivery system on metastatic bone tumors.

  2022cites this paper
• Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.

  2022cites this paper
• Bone loss induced by cancer treatments in breast and prostate cancer patients

  2022cites this paper
• RANK pathway in cancer: underlying resistance and therapeutic approaches

  2022cites this paper
• Effects of NF-κB manipulation on cancer-associated bone disease

  2022cites this paper
• Managing Bone Health in Breast Cancer.

  2022cites this paper
• Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials

  2022cites this paper
• Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer

  2022influential citation
• Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis

  2022cites this paper
• Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.

  2022cites this paper
• Current perspectives on skeletal health and cancer progression Current perspectives on skeletal health and cancer progression across the disease continuum in breast cancer—The role of across the disease continuum in breast cancer—The role of bisphosphonates bisphosphonates

  2022cites this paper
• Impact of breast cancer and its treatment on bone loss and fracture risk—pathophysiology and management

  2021cites this paper
• Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey

  2021cites this paper
• Sarcomas of Bone and Soft Tissues in Children and Adolescents

  2021cites this paper
• Early Denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: A case-control retrospective study

  2021influential citation
• Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials

  2021cites this paper
• Osteoporosis Management with Focus on Spine

  2021cites this paper
• Bone-modifying Agents (BMAs) in Breast Cancer.

  2021cites this paper
• Is denosumab associated with an increased risk for infection in patients with low bone mineral density? A systematic review and meta‐analysis of randomized controlled trials

  2021cites this paper
• Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women

  2021cites this paper
• Molecular Targeted Therapy for the Bone Loss Secondary to Pyogenic Spondylodiscitis Using Medications for Osteoporosis: A Literature Review

  2021cites this paper
• Denosumab Treatment for Giant Cell Tumors, Aneurysmal Bone Cysts, and Fibrous Dysplasia—Risks and Benefits

  2021cites this paper
• Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation

  2021cites this paper
• Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis.

  2021cites this paper
• Perils of Prolonged Ovarian Suppression and Hypoestrogenism in the Treatment of Breast Cancer: Is the Risk of Treatment Worse than the Risk of Recurrence?

  2021cites this paper
• Combining immune checkpoint inhibitors with denosumab: a new era in repurposing denosumab in oncology?

  2020cites this paper
• Integration of denosumab therapy in the management of giant cell tumors of bone.

  2020cites this paper
• Strategies for New Agent Development in Pediatric Sarcomas

  2020cites this paper
• Risk for Infections During Treatment With Denosumab for Osteoporosis: a Systematic Review and Meta-analysis.

  2020cites this paper
• Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials

  2020cites this paper
• Endocrine Therapy-related Endocrinopathies-Biology, Prevalence and Implications for the Management of Breast Cancer.

  2020cites this paper
• The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn

  2020cites this paper
• NF-κB in the New Era of Cancer Therapy.

  2020cites this paper
• Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments

  2020cites this paper
• A Pooled Analysis of Fall Incidence From Placebo‐Controlled Trials of Denosumab

  2020cites this paper
• Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer

  2020cites this paper
• OPG-Fc treatment partially rescues low bone mass phenotype in mature Bgn/Fmod deficient mice but is deleterious to the young mouse skeleton.

  2020cites this paper
• Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases.

  2020cites this paper
• Pharmacological mechanisms of therapeutics

  2020cites this paper
• Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta‐Analysis of Randomized Trials

  2020cites this paper
• Denosumab for cancer-related bone loss

  2020cites this paper
• The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results

  2020cites this paper
• The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL

  2020cites this paper
• Management of osteoporosis in women with breast cancer

  2020cites this paper
• Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.

  2020cites this paper
• Breast cancer patients receiving denosumab during adjuvant aromatase inhibitors treatment: who are the "inadequate responders" patients to denosumab?

  2020cites this paper
• Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective

  2020cites this paper
• Denosumab in breast cancer patients receiving aromatase inhibitors: A single-center observational study of effectiveness in adjuvant setting

  2020cites this paper
• Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)

  2020cites this paper
• Challenges in preventing bone loss induced by aromatase inhibitors.

  2020cites this paper
• Bone turnover markers

  2020cites this paper
• Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice?

  2020cites this paper
• Adjuvant Systemic Therapy: Endocrine Therapy

  2019cites this paper
• Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials

  2019cites this paper
• Prevention and Treatment of Skeletal Complications

  2019cites this paper
• Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment

  2019cites this paper